Navigation Links
Risks Associated With Face Transplants May Be Lower Than Previously Thought, ASPS Journal Review Suggests
Date:10/10/2007

ARLINGTON HEIGHTS, Ill., Oct. 10 /PRNewswire-USNewswire/ -- Face transplants, once on the fringe of medicine, may eventually become more mainstream because of new estimates that suggest the risk of tissue rejection might be lower than previously thought, according to a recent review in Plastic and Reconstructive Surgery(R) (PRS), the official medical journal of the American Society of Plastic Surgeons (ASPS).

"We can only know the true immunological risks associated with face transplants by carefully observing those who have already had the procedure," said ASPS President Roxanne Guy, MD. "While this paper doesn't provide conclusive evidence of the immunological risks, it will help us move forward in making face transplants part of mainstream medicine."

Currently, immunosuppressive drugs are the biggest barrier the medical community faces in performing any transplant because the potential long-term side effects of these medications can make the risk too great.

The authors suggest previous immunological risk projections are inaccurate because they were based on immunosuppression drug regimes that are different than the regimes that will be required of face transplant patients.

When utilizing an immunosuppressive drug regimen consistent with face transplant recipient requirements, the authors believe patients would have a relatively low risk of chronic or continual rejection after surgery -- less than 10 percent. In addition, advances in immunosuppression therapies have increased the capacity to manage face transplant patients and potentially reduce acute or immediate rejection episodes.

The authors also suggest that the immunological risks are lower because face transplant patients may on average be healthier and less likely to suffer from extenuating health issues. Organ transplant recipients, on the other hand, often are extremely sick and have numerous, pre-existing health conditions that make them more susceptible to the
'/>"/>

SOURCE American Society of Plastic Surgeons
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Controlling the Spread of Healthcare Associated Methicillin Resistant Staphylococcus aureus Requires Active Surveillance
2. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
3. Byetta Treatment for Three and a Half Years Associated with Reductions in Cardiovascular Risk Factors in People with Type 2 Diabetes
4. Neurogen Proprietary Insomnia Compound Data for Two Studies Presented at Associated Professional Sleep Societies Annual Meeting
5. Neurogen Proprietary Insomnia Compound Data Presented at Associated Professional Sleep Societies Annual Meeting
6. NCI Researchers Discover Genes That Are Turned on at High Levels in Tumor-associated Blood Vessels of Mice and Humans
7. Vanda Pharmaceuticals To Present Data on VEC-162 at SLEEP 2007, the Annual Meeting of the Associated Professional Sleep Societies
8. Pooled Studies Showed Desvenlafaxine Succinate Significantly Improved Painful Symptoms and Anxious Symptoms Associated with Major Depressive Disorder in Adults, Compared With Placebo
9. Clinical Trial Results Suggest Long-Term Treatment Benefit of Tetrabenazine for Chorea Associated with Huntingtons Disease
10. Cephalon Presents Positive Results for Fentora in Breakthrough Pain Associated with Neuropathic Conditions
11. Insmed Releases Positive Results from Iplex Phase II HIV-Associated Adipose Redistribution Syndrome Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Arrayit Diagnostics Announces Sponsored Research Agreement With Wayne State University and Arrayit Corporation 2Arrayit Diagnostics Announces Sponsored Research Agreement With Wayne State University and Arrayit Corporation 3Arrayit Diagnostics Announces Sponsored Research Agreement With Wayne State University and Arrayit Corporation 4Vivakor Announces New Acquisition Strategy 2Anesiva Completes Sale of its Zingo(TM) Assets to Powder Pharmaceuticals and Lee's Pharmaceuticals 2YM BIOSCIENCES ANNOUNCES OFFER FOR CYTOPIA LTD AN AUSTRALIAN CANCER FOCUSED DEVELOPMENT COMPANY 14357 1YM BIOSCIENCES ANNOUNCES OFFER FOR CYTOPIA LTD AN AUSTRALIAN CANCER FOCUSED DEVELOPMENT COMPANY 14357 2YM BIOSCIENCES ANNOUNCES OFFER FOR CYTOPIA LTD AN AUSTRALIAN CANCER FOCUSED DEVELOPMENT COMPANY 14357 3YM BIOSCIENCES ANNOUNCES OFFER FOR CYTOPIA LTD AN AUSTRALIAN CANCER FOCUSED DEVELOPMENT COMPANY 14357 4YM BIOSCIENCES ANNOUNCES OFFER FOR CYTOPIA LTD AN AUSTRALIAN CANCER FOCUSED DEVELOPMENT COMPANY 14357 5YM BIOSCIENCES ANNOUNCES OFFER FOR CYTOPIA LTD AN AUSTRALIAN CANCER FOCUSED DEVELOPMENT COMPANY 14357 6U S FDA Authorizes Expansion to 40 Clinical Sites for HeartWare U S Bridge to Transplant Clinical Trial 5241 1U S FDA Authorizes Expansion to 40 Clinical Sites for HeartWare U S Bridge to Transplant Clinical Trial 5241 2U S FDA Authorizes Expansion to 40 Clinical Sites for HeartWare U S Bridge to Transplant Clinical Trial 5241 3New Hampshire Rx Card Launching Statewide 5239 1New Hampshire Rx Card Launching Statewide 5239 2